Is Kronos Bio, Inc. (KRON) a Buy, Sell, or Hold?
NASDAQ : KRON
Kronos Bio, Inc.
$0.88 USD
$0.01 (1.49%)
- Volume
- 53.69K
- Average Volume
- 855.96K
- Market Capitalization
- $53.65M
- P/E Ratio
- -0.62
- Dividend Yield
- 0.00%
- Price Target
- $1.63
- Year High
- $1.46
- Year Low
- $0.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.54
Insider Activity Summary (Last 12 Months)
Insiders Buying
20
Insiders Selling
71
Amount of Insider Selling
$5.79M
KRON Insider Buying/Selling by Quarter
KRON Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Belldegrun Arie | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| Belldegrun Arie | director | 2025-06-20 | D-Return | 24.18 | 2025-06-20 |
| Belldegrun Arie | director | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| Belldegrun Arie | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| Belldegrun Arie | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | director, 10 percent owner: | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | director, 10 percent owner: | 2025-06-20 | D-Return | 30.78 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | director, 10 percent owner: | 2025-06-20 | D-Return | 7.3 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | director, 10 percent owner: | 2025-06-20 | D-Return | 2.09 | 2025-06-20 |
| BISCHOFBERGER NORBERT W | director, 10 percent owner: | 2025-06-20 | D-Return | 1.08 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | D-Return | 13.346 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | D-Return | 24.18 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| Ridloff Elena | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | D-Return | 4.1422 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | D-Return | 24.18 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| TANEN DAVID M | director | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| Blunt Roshawn A. | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| Blunt Roshawn A. | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| Blunt Roshawn A. | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| Blunt Roshawn A. | director | 2025-06-20 | D-Return | 17.1 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | D-Return | 28.58 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | D-Return | 24.18 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| Yang Taiyin | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| Kazam Joshua A | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| Kazam Joshua A | director | 2025-06-20 | D-Return | 3.53 | 2025-06-20 |
| Kazam Joshua A | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| Kazam Joshua A | director | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| Kazam Joshua A | director | 2025-06-20 | D-Return | 24.18 | 2025-06-20 |
| Stultz Katherine V | director | 2025-06-20 | D-Return | 1.29 | 2025-06-20 |
| Stultz Katherine V | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| Stultz Katherine V | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| KNOBELMAN DEBORAH | officer: President & Interim CEO | 2025-06-20 | U-Tender | 0.57 | 2025-06-20 |
| KNOBELMAN DEBORAH | officer: President & Interim CEO | 2025-06-20 | D-Return | 0.745 | 2025-06-20 |
| DANSEY ROGER D | director | 2025-06-20 | D-Return | 0.95 | 2025-06-20 |
| DANSEY ROGER D | director | 2025-06-20 | D-Return | 1.28 | 2025-06-20 |
| DANSEY ROGER D | director | 2025-06-20 | D-Return | 1.48 | 2025-06-20 |
| KNOBELMAN DEBORAH | officer: President & Interim CEO | 2025-06-05 | S-Sale | 0.8678 | 2025-06-06 |
| Frisbee Allison | officer: Chief Administrative Officer | 2024-10-15 | A-Award | 0.96 | 2024-10-15 |
| Lin Charles Y | officer: Chief Scientific Officer | 2024-10-15 | A-Award | 0.96 | 2024-10-15 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-06-28 | P-Purchase | 1.2457 | 2024-07-01 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-06-27 | P-Purchase | 1.1655 | 2024-07-01 |
| Ridloff Elena | director | 2024-06-25 | A-Award | 0 | 2024-06-26 |
| Ridloff Elena | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| DANSEY ROGER D | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| Stultz Katherine V | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| Yang Taiyin | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| Blunt Roshawn A. | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| Kazam Joshua A | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| Belldegrun Arie | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| TANEN DAVID M | director | 2024-06-25 | A-Award | 0.95 | 2024-06-26 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-06-12 | P-Purchase | 1.2428 | 2024-06-12 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-06-11 | P-Purchase | 1.0944 | 2024-06-12 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-06-10 | P-Purchase | 0.8764 | 2024-06-12 |
| KNOBELMAN DEBORAH | officer: Chief Financial Officer | 2024-06-03 | A-Award | 0.745 | 2024-06-04 |
| KNOBELMAN DEBORAH | officer: Chief Financial Officer | 2024-06-03 | A-Award | 0 | 2024-06-04 |
| KNOBELMAN DEBORAH | 2024-06-03 | 0 | 2024-06-04 | ||
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-21 | S-Sale | 1.0539 | 2024-02-23 |
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-16 | 0 | 2024-02-23 | |
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-16 | 8.99 | 2024-02-23 | |
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-16 | 5.02 | 2024-02-23 | |
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-16 | 2.09 | 2024-02-23 | |
| Olek Elizabeth A | officer: SR VP, CLINICAL SCIENCE | 2024-02-16 | 1.08 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-21 | S-Sale | 1.0539 | 2024-02-23 |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 0 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 28.82 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 7.08 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 2.53 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 1.08 | 2024-02-23 | |
| Lin Charles Y | officer: SR VP, RESEARCH & DEVELOPMENT | 2024-02-16 | 2.09 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-21 | S-Sale | 1.0539 | 2024-02-23 |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 0 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 4.32 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 7.08 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 5.02 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 2.09 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 13.346 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 28.82 | 2024-02-23 | |
| Frisbee Allison | officer: SR VP, CORP OPERATIONS & LEGAL | 2024-02-16 | 1.08 | 2024-02-23 | |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-02-15 | A-Award | 0 | 2024-02-16 |
| BISCHOFBERGER NORBERT W | director, officer: PRESIDENT & CEO | 2024-02-15 | A-Award | 1.08 | 2024-02-16 |
| Dinsmore Christopher | officer: Chief Scientific Officer | 2024-01-04 | S-Sale | 1.1836 | 2024-01-05 |
| DiMartino Jorge | officer: Chief Medical Officer & VP | 2024-01-04 | S-Sale | 1.1836 | 2024-01-05 |
| Kosacz Barbara | officer: COO & General Counsel | 2024-01-04 | S-Sale | 1.1836 | 2024-01-05 |
| Dinsmore Christopher | officer: Chief Scientific Officer | 2023-12-12 | S-Sale | 1.305 | 2023-12-13 |
| DiMartino Jorge | officer: Chief Medical Officer & VP | 2023-12-12 | S-Sale | 1.305 | 2023-12-13 |
| BISCHOFBERGER NORBERT W | director, officer: President & CEO | 2023-11-17 | P-Purchase | 1.084 | 2023-11-17 |
| BISCHOFBERGER NORBERT W | director, officer: President & CEO | 2023-11-16 | P-Purchase | 0.9965 | 2023-11-17 |
| BISCHOFBERGER NORBERT W | director, officer: President & CEO | 2023-11-15 | P-Purchase | 0.8045 | 2023-11-17 |
| GARDINER SANDRA A. | officer | 2023-09-15 | 0 | 2023-09-18 | |
| Dinsmore Christopher | officer: Chief Scientific Officer | 2023-07-06 | S-Sale | 1.7523 | 2023-07-07 |
| DiMartino Jorge | officer: Chief Medical Officer & VP | 2023-07-06 | S-Sale | 1.7523 | 2023-07-07 |